Dietary Supplements

Browse Dietary Supplements Content

CHPA charged IOM to develop a proposed framework for categorizing and prioritizing DS ingredients based on safety issues, describe a process for developing a system of scientific reviews for evaluating the safety of DS ingredients, and develop at least six scientific reviews as prototypes for the system.

Oct 11, 2001

Comments before the White House Commission on Complementary and Alternative Medicine Policy on information development and dissemination.

Mar 26, 2001

CHPA submits these written comments in response to FDA’s notice in the Federal Register concerning “Guidance for Industry: Significant Scientific Agreement in the Review of Health Claims for Conventional Foods and Dietary Supplements.”

Feb 22, 2000

Orange CHPA logo on dark blue background

Learn more about the issues CHPA addresses in the OTC medicine, dietary supplement, and consumer medical device industries.

Learn about CHPA's current slate of federal legislative priorities including OTC regulatory reform, dietary supplement regulation modernization, supply chain and product integrity, and more.

Advertising and marketing of dietary supplements are regulated by the FDA, the FTC, and other governmental organizations. Products must be deemed safe prior to marketing and advertisement claims must be substantiated.

Informed Consumer Decision Making

The following information on botanical ingredients should be included in either a bulk botanical raw material specification sheet (for business-to-business transactions) or finished product labeling (when selling directly to consumers).

Product Safety & Integrity

Consumer Healthcare Products Association members agree voluntarily to the following provisions pertaining to pyrrolizidine alkaloids.

Filter Results